NMT Medical Says It Shuts Down PFO/Migraine Trial And Increases Investment In PFO/Stroke Trial - Quick Facts

(RTTNews) - NMT Medical, Inc. (NMTI | news | PowerRating | PR Charts ) on Wednesday said it is closing down its patent foramen ovale/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity. The company expects the move to save nearly $14 million over the next two to three years as it redistributes investments originally budgeted for MIST II.

The company noted that a portion of the savings would be used to further finance CLOSURE I, the company's pivotal PFO/stroke and transient ischemic attack clinical trial nearing enrollment completion in the U.S.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index